CytoSorbents Corporation (CTSO)

[techxen]

On or before the next earnings call, the stock should have at least a temporary increase in price if they (A) announce finally that the HemoDefend IDE has been submitted and approved. This removes a lot of uncertainty and finally puts a stake in the ground for the trial to actually get started, (B) provide an update on an execution plan and any revisions to the REFRESH 2 trial and a timeline for resuming, or (C) provide an indication as to whether the REMOVE trial achieved their primary endpoint and if the over-enrollment is complete, which would provide a indication of a positive readout sometime in the next several months. There is always the possibility of a black swan event such as a CAR-T partnership announcement that could be a significant catalyst, but I would temper my expectations for such.

In short there is really no identifiable catalyst until some of these major trials get further along, or if something new comes out of the next earnings call.